<SEC-DOCUMENT>0001140361-23-051195.txt : 20231102
<SEC-HEADER>0001140361-23-051195.hdr.sgml : 20231102
<ACCEPTANCE-DATETIME>20231102170027
ACCESSION NUMBER:		0001140361-23-051195
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231030
ITEM INFORMATION:		Changes in Registrant's Certifying Accountant
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231102
DATE AS OF CHANGE:		20231102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GYRE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231373396

	BUSINESS ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE, SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		650-266-8674

	MAIL ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE, SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20150820

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ny20009756x13_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:gyre="http://ir.catalystbiosciences.com/20231030" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_d7ef9904c8594c1ead2b7dc5a7f681f6" contextRef="c20231030to20231030" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_c9ba9617c3d64be59d69c656ec029ea6" contextRef="c20231030to20231030">GYRE THERAPEUTICS, INC.</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_a508e00632ee49239324622d3271b368" contextRef="c20231030to20231030">0001124105</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_625bf256eef24b09a289a1177a11d53c" contextRef="c20231030to20231030">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="gyre-20231030.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20231030to20231030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div> <br />
    </div>

    <div>
      <div>
        <div style="text-align: left;"><br />
        </div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">UNITED STATES<span style="font-size: 18pt; font-family: 'Times New Roman', Times, serif;"><br />
        </span>SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"> <br />
      </div>

      <div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">
          <hr style="height: 1px; width: 20%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" />
<div>&#160;FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_59830fad38ff4f59b595d91425a33430" contextRef="c20231030to20231030">8-K</ix:nonNumeric></div>
</div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">
        <hr style="height: 1px; width: 20%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

      <div>
        <div><br />
        </div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">CURRENT REPORT<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br />
        </span>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Date of report (Date of earliest event reported): <span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_55367c8c4ef344a0a39de8bafe7c64aa" contextRef="c20231030to20231030" format="ixt:date-monthname-day-year-en">October 30, 2023</ix:nonNumeric></span></div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_c9ba9617c3d64be59d69c656ec029ea6">Gyre Therapeutics, Inc.</span><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Exact name of registrant as specified in its charter)</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.01%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_bbb7053f2737452899c5aa15f4d05ad7" contextRef="c20231030to20231030" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>
            </td>

    <td style="width: 32%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_f626db677e654745b1f25cbc372d7e28" contextRef="c20231030to20231030">000-51173</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>
            </td>

    <td style="width: 32%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_4732621c43af477f8b8d95e8d887d283" contextRef="c20231030to20231030">56-2020050</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 32.01%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(State or other jurisdiction<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br />
                </span>of incorporation)</div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>
            </td>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Commission<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br />
                </span>File Number)</div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>
            </td>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(IRS Employer<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br />
                </span>Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom;">
              <div>
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_42d4a61ef0d0414e847dada451ee0ecc" contextRef="c20231030to20231030">12730 High Bluff Drive</ix:nonNumeric><br />
                </div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_b6420c2c7108463ebd3cab7583dd3bfb" contextRef="c20231030to20231030">Suite 250</ix:nonNumeric><br />
                </div>
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_d9459c1ac595466c8575ccc8949b2627" contextRef="c20231030to20231030">San Diego</ix:nonNumeric>,
                  <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_3809a507a8884f58814c1dd91f96414e" contextRef="c20231030to20231030">CA</ix:nonNumeric></div>
              </div>
            </td>

    <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>
            </td>

    <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_7846919d00c446e1913d5845494c1ff7" contextRef="c20231030to20231030">92130</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Address of principal executive offices)</div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>
            </td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Registrant&#8217;s telephone number, including area code: <span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_e266b178ed654806ba10f1386a52d54d" contextRef="c20231030to20231030">650</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_23dfd9058e894c60ad97bf32242aa3a4" contextRef="c20231030to20231030">266-8674</ix:nonNumeric></span></div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Catalyst Biosciences, Inc.</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">12730 High Bluff Drive</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Suite 250</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">San Diego, CA</span>&#160;<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">92130</span></div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">(Former name or former address, if changed since last report)</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div>
        <div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
        following provisions (<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">see</span>&#160;General Instruction A.2. below):</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_da6b7a27461c4e46943060825e9f4ed4" contextRef="c20231030to20231030" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Written communications pursuant to Rule 425
        under the Securities Act (17 CFR 230.425)</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_53b5741562014547a62e9d227fb969d4" contextRef="c20231030to20231030" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12
        under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_833f09131d9448e1a4dcb637b4571dd4" contextRef="c20231030to20231030" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Pre-commencement communications pursuant to
        Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_26ef1c56dd164887b7494a6cecb80424" contextRef="c20231030to20231030" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Pre-commencement communications pursuant to
        Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 34%; vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Title of each class</span></div>
            </td>

    <td style="width: 2.01%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trading Symbol(s)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name of each exchange on which<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br />
                </span>registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_509b5ea56bd249d0be1f104fe1f41ea1" contextRef="c20231030to20231030">Common Stock</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2.01%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_597fad79c171459b934b66c3ac950071" contextRef="c20231030to20231030">GYRE</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_625bf256eef24b09a289a1177a11d53c">The Nasdaq Capital Market</span><br />
              </div>
            </td>

  </tr>


</table>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
        or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_6d41e48e945b4148a2e25eb983f553da" contextRef="c20231030to20231030" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
        revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9744;</span></div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
<div>&#160;
        </div>
<hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      <div style="text-align: center;"><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div>&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Introductory Note</div>

      <div>&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As previously reported, on October 30, 2023 (the &#8220;Closing Date&#8221;), Gyre Therapeutics, Inc. (formerly known as Catalyst Biosciences, Inc.) (prior to the
        Closing Date, &#8220;Catalyst&#8221; and after the Closing Date, &#8220;Gyre&#8221;) consummated the previously announced business combination (the &#8220;Closing&#8221;) pursuant to that certain Business Combination Agreement (the &#8220;Business Combination Agreement&#8221;), dated as of
        December 26, 2022 and as amended on March 29, 2023 and August 30, 2023.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 4.01 Changes in Registrant&#8217;s Certifying Accountant.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(a)&#160;Dismissal of Independent Registered Public Accounting Firm</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to the Closing Date, EisnerAmper LLP (&#8220;EisnerAmper&#8221;) served as the independent registered public accounting firm of Catalyst. On the Closing Date,
        following the completion of Catalyst&#8217;s audit for the year ended December 31, 2022 and the subsequent interim periods through September 30, 2023, which consisted only of the accounts of Catalyst, and the filing of Catalyst&#8217;s Annual Report on Form
        10-K for the year ended December 31, 2022 and Catalyst&#8217;s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, the Audit Committee (the &#8220;Audit Committee&#8221;) of Gyre&#8217;s board of directors dismissed
        EisnerAmper as Gyre&#8217;s independent registered public accounting firm.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">EisnerAmper&#8217;s reports on Catalyst&#8217;s (the &#8220;Company&#8221;) consolidated financial statements as of and for the years ended December 31, 2022 and 2021 did not
        contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles, except for the following:</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i) EisnerAmper&#8217;s report on Catalyst&#8217;s consolidated financial statements as of and for the years ended December 31, 2022 and 2021, contained a separate
        paragraph stating that &#8220;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.&#160; As discussed in Note 2 to the financial statements, the terms of the Convertible Preferred Stock include a
        cash settlement feature which, provide that, if the Company&#8217;s stockholders fail to approve the conversion of the Convertible Preferred Stock by September 30, 2023, the Company could be required to make cash payments to the holders of the
        Convertible Preferred Stock significantly in excess of its current liquidity, which raises substantial doubt about its ability to continue as a going concern.&#160; Management&#8217;s plans in regard to these matters are also described in Note 2.&#160; The
        financial statements do not include any adjustments that might result from the outcome of this uncertainty.&#8221;</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii) The accompanying notes to Catalyst&#8217;s unaudited condensed consolidated financial statements as of and for the quarters ended March 31, 2023 and June
        30, 2023 both contained language stating that &#8220;However, as the vote of the Company&#8217;s common stockholders is outside of the control of the Company, there is substantial doubt about its ability to continue as a going concern for at least 12 months
        following the issuance of these condensed consolidated financial statements. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of
        liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of
        liabilities that might result from the outcome of this uncertainty.&#8221;</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii) The accompanying notes to Catalyst&#8217;s unaudited condensed consolidated financial statements as of and for the quarter ended September 30, 2023
        contained language stating that &#8220;As part of the Business Combination Agreement, GNI agreed to share certain ongoing operating expenses incurred by the Company until the Business Combination Agreement closes. See Note 12, Related Parties, for
        additional information regarding this arrangement. The actual amount and timing of the cost sharing payments from GNI is outside of the control of the Company. Given the uncertainties related to the pending Business Combination Agreement, there is
        substantial doubt about the Company&#8217;s ability to continue as a going concern for at least 12 months following the issuance of these condensed consolidated financial statements. The accompanying condensed consolidated financial statements have been
        prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the
        recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&#8221;</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2022 and 2021, and the subsequent interim period through September 30, 2023, there were: (i) no disagreements, within
        the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions, between Catalyst and EisnerAmper on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not
        resolved to EisnerAmper&#8217;s satisfaction, would have caused EisnerAmper to make reference thereto in its reports; and (ii) no &#8220;reportable events&#8221; within the meaning of Item 304(a)(1)(v) of Regulation S-K.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Catalyst has requested that EisnerAmper furnish a letter addressed to the SEC stating whether or not it agrees with the above statements. A copy of such
        letter, dated November 2, 2023, is filed as Exhibit 16.1 to this Current Report on Form 8-K.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(b)&#160;Engagement of Independent Registered Public Accounting Firm</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On the Closing Date, the Audit Committee engaged Grant Thornton Zhitong Certified Public Accountants LLP (&#8220;Grant Thornton&#8221;) as Gyre&#8217;s independent
        registered public accounting firm.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2022 and 2021, and the subsequent interim period through September 30, 2023, neither Gyre nor anyone on its behalf
        has consulted with Grant Thornton regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on Gyre&#8217;s financial statements, and neither a
        written report nor oral advice was provided to Gyre that Grant Thornton concluded was an important factor considered by Gyre in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject
        of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions; or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
        Arrangements of Certain Officers.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Departure of Certain Officers</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As previously reported, immediately prior to and effective upon the Closing, Nassim Usman, Ph.D., Catalyst&#8217;s President and Chief Executive Officer,
        ceased to be an officer of Gyre but is remaining a director of Gyre. Catalyst previously entered into an offer letter with Dr. Usman, pursuant to which he became eligible to receive severance benefits upon a qualifying termination of employment.
        Accordingly, in connection with the Transactions, on the Closing Date, Dr. Usman entered into a separation and release of claims agreement, which provides for (i) payment by Catalyst of an amount equivalent to his annual base salary for twelve
        months, (ii) payment by Catalyst of an amount equivalent to eighteen months of COBRA premium payments, as if Dr. Usman had remained an active employee, and (iii) accelerated vesting of the portion of any stock options held by Dr. Usman as of the
        termination date that were scheduled to vest during the twelve month period following Dr. Usman&#8217;s termination date, had he remained employed during such time. In addition, the period of time during which Dr. Usman&#8217;s vested stock options will remain
        exercisable in accordance with the terms of the applicable award agreements governing such option will commence as of the last day of his service as a director of Gyre.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As previously reported, immediately prior to and effective upon the Closing, Seline Miller, Catalyst&#8217;s Interim Chief Financial Officer, ceased to be an
        officer of Gyre. Catalyst previously entered into an amended employment agreement with Ms. Miller, pursuant to which she became eligible to receive severance benefits upon a qualifying termination of employment. Accordingly, in connection with the
        Transactions, on November 1, 2023, Ms. Miller entered into a separation and release of claims agreement with Gyre, which provides for (i) continued payment of her annual base salary for nine months, (ii) for up to 12 months, reimbursement of
        premium payments, as if Ms. Miller had remained an active employee, for any COBRA coverage that she timely elects, and (iii) accelerated vesting of the portion of any stock options held by Ms. Miller as of the termination date that were scheduled
        to vest during the nine month period following Ms. Miller&#8217;s termination date, had she remained employed during such time. In addition, the period of time during which Ms. Miller&#8217;s vested stock options will remain exercisable in accordance with the
        terms of the applicable award agreements governing such options will commence on March 31, 2024.</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The foregoing descriptions of the separation agreements with Dr. Usman and Ms. Miller contained herein do not purport to be complete and are qualified in
        their respective entireties by reference to the complete text of their agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01 Financial Statements and Exhibits.</div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(d) Exhibits</div>

      <div style="text-align: justify;"><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">EXHIBIT INDEX</div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); width: 792px;">


  <tr>

    <td style="width: 174.516px; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit Number</div>
              </td>

    <td style="width: 8.10938px; vertical-align: top; white-space: nowrap;">&#160;</td>

    <td style="width: 1116.38px; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
              </td>

  </tr>

  <tr>

    <td style="width: 174.516px; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20009756x13_ex10-1.htm">10.1+</a></div>
                </div>
              </td>

    <td style="width: 8.10938px; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 1116.38px; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Usman Separation Agreement.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="background-color: rgb(204, 238, 255); vertical-align: top; width: 174.516px;">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20009756x13_ex10-2.htm">10.2+</a></div>
              </td>

    <td style="background-color: rgb(204, 238, 255); vertical-align: top; white-space: nowrap; width: 8.10938px;">&#160;</td>

    <td style="background-color: rgb(204, 238, 255); vertical-align: top; width: 1116.38px;">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Miller Separation Agreement.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 174.516px; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20009756x13_ex16-1.htm">16.1</a></div>
              </td>

    <td style="width: 8.10938px; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 1116.38px; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Letter to the SEC from EisnerAmper LLP, dated November 2, 2023.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 174.516px; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
                </div>
              </td>

    <td style="width: 8.10938px; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td style="width: 1116.38px; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (formatted as Inline XBRL).</div>
                </div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">+</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Indicates a management contract.</span></div>

      <div><br />
      </div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned hereunto duly authorized.</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 46.4%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 53.6%; vertical-align: bottom;" colspan="2">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gyre Therapeutics, Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 46.4%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 53.6%; vertical-align: bottom;" colspan="2">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 46.4%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: November 2, 2023</div>
            </td>

    <td style="width: 5.5%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
            </td>

    <td style="width: 48.11%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Charles Wu</div>
            </td>

  </tr>

  <tr>

    <td style="width: 46.4%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 5.5%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name:</div>
            </td>

    <td style="width: 48.11%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Charles Wu, Ph.D.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 46.4%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 5.5%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:</div>
            </td>

    <td style="width: 48.11%; vertical-align: bottom;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Executive Officer</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /> </div>

      <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>

    </div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ny20009756x13_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit 10.1</div>
      <div><br>
      </div>
      <div style="text-align: left; color: #2E5395; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Separation Benefits</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The documents in this section pertain to both (1) your last pay check and (2) your severance benefits.</div>
      <div><br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Highlights:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z040ff461a77d472a86ed8e8676d14d25">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Your formal last day of employment will be effective October 30, 202<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3.</font></div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z960dc34c060446e6898d6cb0eff47895">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We request that we receive your signed <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Exit
                  Paperwork </font>via Adobe Sign no later than October 30, 2023.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb8a494220974471596c63cd3788d8cb9">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In order to receive your severance and retention bonus, your signature is required on the digital <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Separation Agreement </font>via Adobe Sign which will be emailed to you.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0575e121c74e42108aa02aa90cded857">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Please <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>DO NOT</u></font> sign your <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Separation Agreement </font>before October 30, 2023; any agreement signed prior to your last date of employment is invalid and will need to be reprocessed and re-signed.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z71cf800f737e4431af8010858e530280">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">You will have 2<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1 </font>days from October 30<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">,</font> 2023 to consider and sign your <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Separation Agreement </font>before it
                expires.&#160; Further, you have seven (7) days from the signature date to revoke your signature.&#160; Therefore, severance benefits cannot be paid until the revocation period has elapsed.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gyre Therapeutics, Inc.</div>
      <div><br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">October 30, 2023</div>
      <div style="text-align: left;"><br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. Nassim Usman, Ph.D.</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">965 Elsinore Drive</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Palo Alto, CA 94303</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1032df051b134ad5b93307956b2e7ffb">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Re:</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Separation Agreement</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dear Nassim:</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This letter sets forth the substance of the separation agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Agreement</font>&#8221;) that Gyre Therapeutics, Inc. (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company</font>&#8221;) is offering to you to aid in your employment
        transition.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">SEPARATION DATE.&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Your



            last day of employment with the Company and your employment termination date will be October 30, 2023 (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Separation Date</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8221;).&#160; Following the Separation Date you will no longer be an employee of the Company</font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided that</font>, subject to your election by the stockholders of the Company as a Class II director at the special meeting of stockholders of the Company being held on August 29, 2023, you shall continue
          to serve as a non-employee member of the board of directors of the Company until the Company&#8217;s 2026 Annual Meeting of Stockholders and until your successor is duly elected and qualified or until your earlier resignation or removal.&#160; The date your
          service with the Company as a non-employee member of the board of directors of the Company terminates is referred to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Last Day of
            Service</font>.&#8221;&#160; The period from the Separation Date through the Last Day of Service is referred to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Non-Employee Director Period</font>.&#8221;&#160;



          After the Separation Date, you agree that you will not represent to anyone that you are still an employee or officer of the Company and you will not say or do anything purporting to bind the Company or any of its affiliates, other than in your
          capacity as a non-employee director during the Non-Employee Director Period<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.&#160; On the Separation Date, the Company will pay you all accrued salary, and
            all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings.&#160; You are entitled to these payments regardless of whether or not you sign this Agreement.</font></font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">SEVERANCE BENEFITS.&#160; </font>If you timely sign this Agreement and allow the releases set forth herein to become
          effective, then in full satisfaction of any obligations for the Company to provide you with severance benefits for a termination without Cause outside of a Change in Control Protection Period (as defined in your employment offer letter dated
          August 27, 2018, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Offer Letter</font>&#8221;)) as set forth in your Offer Letter, the Company will provide you with the following severance
          benefits<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">:</font></font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Severance Pay.&#160; </font>The Company will pay you an amount equal to the sum of (i) twelve (12) months of your base
          salary in effect as of the Separation Date, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>plus</u></font> (ii) $203,253.80, which represents the aggregate amount of eighteen (18) months of premiums related to
          continuation coverage under COBRA for you and your eligible dependents based on coverage levels in effect on the Separation Date, subject to standard payroll deductions and withholdings (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Severance Pay</font>&#8221;).&#160; The Severance Pay will be paid to you in a lump sum on the date on which you sign and deliver this Agreement to the Company; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided</font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">however</font>, that if you revoke your acceptance of this Agreement prior to the
          expiration of the revocation period described in Section 12(c), you will be required to repay to the Company one hundred percent (100%) of the Severance Pay, without regard to any taxes previously paid by you with respect thereto.</font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Accelerated Vesting.&#160; </font>You were granted options to purchase shares of the Company&#8217;s common stock (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Options</font>&#8221;) pursuant to the Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Plan</font>&#8221;).&#160; Under the terms of the Plan and your stock option grants, and notwithstanding your service as a non-employee service provider during the Non-Employee Director Period, you hereby acknowledge and agree that
          vesting of your Options will cease as of the Separation Date and your rights to exercise any vested Options shall be as set forth in the applicable stock option grant notice, stock option agreement, and/or the Plans (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Option Documents</font>&#8221;); <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided that</font>,
          notwithstanding anything to the contrary herein, the applicable post-termination exercise period with respect to your Options shall commence as of your Last Day of Service.&#160; Per your Offer Letter, the Company will immediately accelerate as of the
          Separation Date any of the shares underlying the Options that would have vested had you remained an employee of the Company through the date that is twelve (12) months following the Separation Date.&#160; Your Options shall continue to be governed by
          the terms of the applicable Option Documents<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.&#160; Further, you hereby acknowledge and agree that, in accordance with the terms of that certain waiver letter
            agreement by and between you and the Company dated January 17, 2023 (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Waiver Letter Agreement</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8221;), each Option that is outstanding and unvested as of the Separation Date (other than those Options eligible for the acceleration provided in the
            immediately preceding sentence) shall be cancelled effective as of the Separation Date.&#160; Notwithstanding anything to the contrary herein, this Section 2(c) shall not apply to any options to purchase shares of the Company&#8217;s common stock or other
            equity awards granted to you in respect of your service as a non-employee director during the Non-Employee Director Period (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Non-Employee Director Awards</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8221;), and such Non-Employee Director Awards shall remain outstanding and </font>subject to the terms of the
          applicable grant notice(s), the applicable award agreement(s), and/or the applicable equity plan(s)<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.</font></font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">OTHER COMPENSATION OR BENEFITS.&#160; </font>By executing this Agreement, you acknowledge and agree that the Company&#8217;s
          obligations to provide you with any severance benefits or any other payments (including, without limitation, the severance benefits set forth in your Offer Letter) are hereby extinguished (except for the benefits described in this Agreement).&#160;
          You further expressly acknowledge and agree that the severance benefits, and other benefits provided herein are in full and complete satisfaction of the Company&#8217;s obligations, if any, to pay you severance benefits or any other payments pursuant
          to your Offer Letter or any other agreements.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">You acknowledge that, except as expressly provided in this Agreement, you will not receive any additional
            compensation, severance or benefits after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; color: #000000;">e.g</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">., 401(k) account).</font></font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">EXPENSE REIMBURSEMENTS.&#160; </font>You agree that, within the next ten (10) days after the Separation Date, you will
          submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement.&#160; The Company will reimburse you for these expenses pursuant to its
          regular business practice.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">INDEPENDENT CONTRACTOR</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-variant: small-caps;">.</font>&#160; During the Non-Employee Director Period, you acknowledge and agree that your relationship with the Company will be that of an independent contractor and not that of an employee.&#160; As a result, you
          acknowledge and agree that your participation in all employee benefits, including, but not limited to, the accrual of bonuses and vacation/PTO, if any, shall immediately cease as of the Separation Date.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">RETURN OF COMPANY PROPERTY.&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">If requested by the Company, you agree to return to the Company all Company documents (and all copies thereof) and other Company property in your possession or control.&#160; In addition, if you have used any personally owned computer,
            server, or e-mail system to receive, store, review, prepare or transmit any confidential or proprietary data, materials or information of the Company, then within sixty (60) business days after the Separation Date, if requested by the Company,
            you must provide the Company with a computer-useable copy of such information and then permanently delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole or in part), and
            you agree to provide the Company access to your system, as requested, to verify that the necessary copying and deletion is done.&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Your timely compliance with the provisions of this paragraph is a condition to your receipt of the severance benefits provided hereunder. &#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Notwithstanding the foregoing, as an additional benefit to you under this Agreement, you may retain possession of your Company-issued laptop, key card and phone, </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; color: #000000;">provided that</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"> you (a) cooperate with the Company&#8217;s IT department to have all Company data
            removed from the devices (except any such data as may be required in connection with the non-employee services you provide during the </font>Non-Employee Director<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"> Period), and (b) ensure that all Company-related documents in your possession or control are saved onto the Company&#8217;s One Drive account.</font></font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">PROPRIETARY INFORMATION OBLIGATIONS.&#160; </font>You acknowledge your continuing obligations under your Proprietary
          Information and Inventions Agreement, a copy of which is attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exhibit A</font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CONFIDENTIALITY.&#160; </font>The provisions of this Agreement will be held in strictest confidence by you and will not be
          publicized or disclosed in any manner whatsoever; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided, however, </font>that: (a) you may disclose this Agreement to your immediate family; (b)
          you may disclose this Agreement in confidence to your attorneys, accountants, auditors, tax preparers, and financial advisors; (c) you may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise
          required by law; and (d) you may make such statements and disclosures as set forth in the section of this Agreement entitled &#8220;Protected Rights.&#8221;&#160; In particular, and without limitation, you agree not to disclose the terms of this Agreement to any
          current or former Company employee or independent contractor.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NONDISPARAGEMENT.&#160; </font>You agree not to disparage the Company or the Company&#8217;s officers, directors, employees,
          shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided that </font>you may respond accurately and fully to any question, inquiry or request for information when required by legal process and you may make such disclosures as set forth in the section of this Agreement
          entitled &#8220;Protected Rights.&#8221;&#160; In addition, nothing in this provision or this Agreement is intended to prohibit or restrain you in any manner from making disclosures that are protected under the whistleblower provisions of federal or state law or
          regulation.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO VOLUNTARY ADVERSE ACTION.&#160; </font>You agree that you will not voluntarily (except in response to legal compulsion)
          assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or
          agents.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO ADMISSIONS.&#160; </font>You understand and agree that the promises and payments in consideration of this Agreement
          shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">RELEASE OF CLAIMS</font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 68.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">General Release.&#160; </font>In exchange for the consideration provided to you under this Agreement to which you would not
          otherwise be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents,
          attorneys, predecessors, successors, insurers, affiliates, and assigns (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Released Parties</font>&#8221;) from any and all claims,
          liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Released Claims</font>&#8221;).</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 68.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Scope of Release.&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">The



            Released Claims include, but are not limited to: (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment; (ii) all claims related to your compensation or benefits from the
            Company, including salary, bonuses, commissions, vacation, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company; (iii) all claims for breach of
            contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all
            federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended),</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">the federal Americans with Disabilities Act of 1990, </font>the



          federal Age Discrimination in Employment Act of 1967 (as amended) (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ADEA</font>&#8221;), <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended).&#160; You acknowledge that you have been advised, as required by California Government Code Section
            12964.5(b)(4), that you have the right to consult an attorney regarding this Agreement and that you were given a reasonable time period of not less than five (5) business days in which to do so.</font></font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 68.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ADEA Waiver. </font> You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the
          ADEA and that the consideration given for this waiver is in addition to anything of value to which you are already entitled.&#160; You further acknowledge that you have been advised, as required by the ADEA, that: (i) your waiver does not apply to any
          rights or claims that may arise after the date that you sign this Agreement; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (iii) you have twenty-one (21) days to
          consider this Agreement (although you may choose voluntarily to sign it earlier); (iv) you have seven (7) days following the date you sign this Agreement to revoke your acceptance of this Agreement (by providing written notice of your revocation
          to the Company&#8217;s CEO); and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after the date that this Agreement is signed by you <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided that</font> you do not revoke it.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 68.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Section 1542 Waiver.&#160; </font>YOU UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.&#160;
          In giving the release herein, which includes claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code, which reads as follows: <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#8220;A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release,
            which if known by him or her would have materially affected his or her settlement with the debtor or released party.&#8221;&#160; </font>You hereby expressly waive and relinquish all rights and benefits under that section and any law of any other
          jurisdiction of similar effect with respect to your release of any unknown or unsuspected claims herein.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 68.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Excluded Claims.&#160; </font>Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Excluded Claims</font>&#8221;): (i) any rights or claims for indemnification you may have pursuant to any written indemnification agreement with the Company to
          which you are a party or under applicable law; (ii) any rights which are not waivable as a matter of law; and (iii) any claims for breach of this Agreement.&#160; You hereby represent and warrant that, other than the Excluded Claims, you are not aware
          of any claims you have or might have against any of the Released Parties that are not included in the Released Claims.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 68.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Protected Rights.&#160; </font>You understand that nothing in this Agreement limits your ability to file a charge or
          complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or
          local governmental agency or commission (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Government Agencies</font>&#8221;).&#160; You further understand this Agreement does not limit your ability to
          communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.&#160; While this
          Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may
          have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement.&#160; Nothing in this Agreement prevents you from discussing or disclosing information about unlawful acts in the workplace,
          such as harassment or discrimination or any other conduct that you have reason to believe is unlawful.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">REPRESENTATIONS.&#160; </font>You hereby represent that you have been paid all compensation owed and for all hours worked,
          have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">SECTION 409A</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.&#160; </font>The



          payments and benefits under this Agreement are intended to qualify for an exemption from application of Section 409A of the Code or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A
          of the Code, and any ambiguities herein shall be interpreted accordingly.&#160; Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).&#160; The Company makes no
          representation or warranty and shall have no liability to you or any other person if any provisions of this letter are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the
          conditions of such Section.</font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">GENERAL.&#160; </font>This Agreement, including the exhibits attached hereto, together with the Waiver Letter Agreement,
          constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter.&#160; It is entered into without reliance on any promise or representation, written or oral, other than
          those expressly contained herein, and it supersedes any other such promises, warranties or representations.&#160; This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.&#160; This
          Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.&#160; If any provision of this Agreement is
          determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest
          extent permitted by law, consistent with the intent of the parties.&#160; This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of California as applied to contracts made
          and to be performed entirely within California.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If this Agreement is acceptable to you, please sign below and return the original to Michelle Lee, Associate of Orrick, Herrington &amp;
        Sutcliffe LLP within twenty-one (21) days of the Separation Date.</div>
      <div><br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I wish you good luck in your future endeavors.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zcfefe9d2553f4600ae46646991c74fc5">

          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sincerely,</div>
            </td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">GYRE THERAPEUTICS, INC.</div>
            </td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BY:</div>
            </td>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Charles Wu, Ph.D.</div>
            </td>
            <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Charles Wu, Ph.D.</div>
            </td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Executive Officer</div>
            </td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accepted and Agreed:</div>
            </td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BY:</div>
            </td>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Dr. Nassim Usman, Ph.D.</div>
            </td>
            <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. Nassim Usman, Ph.D.</div>
            </td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: October 30, 2023</div>
            </td>
            <td style="width: 70%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ny20009756x13_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 10.2</font><br>
    </div>
    <div style="text-align: right;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: left;"><br>
      <div style="text-align: left; color: #2E5395; font-family: 'Times New Roman', Times, serif; font-size: 14pt;">Separation Benefits</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The documents in this section pertain to both (1) your last pay check and (2) your severance benefits (cash compensation and COBRA).</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Highlights:</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="zc3d14a21b22742dbbefe52129f6c3bc6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 4.98%; text-align: center; vertical-align: middle;">
                <div>&#8226; <br>
                </div>
              </td>
              <td style="width: auto;">
                <div>
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Your formal last day of employment will be effective October 30, 2023<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</font></div>
                </div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 4.98%; text-align: center; vertical-align: middle;">&#160;</td>
              <td rowspan="1" style="width: auto;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 4.98%; text-align: center; vertical-align: middle;">
                <div>&#8226;</div>
              </td>
              <td style="width: auto;">
                <div>
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We request that we receive your signed <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Exit Paperwork </font>via Adobe Sign no later than October 30, 2023<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</font></div>
                </div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 4.98%; text-align: center; vertical-align: middle;">&#160;</td>
              <td rowspan="1" style="width: auto;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 4.98%; text-align: center; vertical-align: middle;">
                <div>&#8226;</div>
              </td>
              <td style="width: auto;">
                <div>
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In order to receive your severance and retention bonus, your signature is required on the digital <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Separation Agreement </font>via Adobe Sign which will be emailed to you.</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="zdff849c13b2f4fedad0dd05fc6eff2ee" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 5%; text-align: center; vertical-align: middle;">
                <div>&#160;<br>
                </div>
              </td>
              <td style="width: 3%; text-align: left; vertical-align: top;">
                <div>o <br>
                </div>
              </td>
              <td style="width: auto; text-align: left; vertical-align: top;">
                <div>Please <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>DO NOT</u></font> sign your <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Separation Agreement </font>before
                  October 30, 2023; any agreement signed prior to your last date of employment is invalid and will need to be reprocessed and re-signed. <br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 5%; text-align: center; vertical-align: middle;">
                <div>&#160;</div>
              </td>
              <td style="width: 3%; text-align: left; vertical-align: top;">
                <div>&#160;</div>
              </td>
              <td style="width: auto; text-align: left; vertical-align: top;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 5%; text-align: center; vertical-align: middle;">
                <div>
                  <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br>
                  </div>
                </div>
              </td>
              <td style="width: 3%; text-align: left; vertical-align: top;">
                <div>o <br>
                </div>
              </td>
              <td style="width: auto; text-align: left; vertical-align: top;">
                <div>You will have 21 days from October 30<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">,</font> 2023 to consider and sign your <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Separation Agreement </font>before it expires.&#160; Further, you have seven (7) days from the signature date to revoke your signature.&#160; Therefore, severance benefits cannot be paid until the revocation period has
                  elapsed. <br>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div style="text-align: center; margin-right: 6.5pt; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold;">Gyre Therapeutics, Inc.</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"> <br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">October 30, 2023</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br>
        </font>Seline Miller<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br>
        </font>9264 Ketay Circle<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br>
        </font>Boca Raton, FL 33428</div>
      <div>&#160;</div>
      <div style="text-align: left;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Re:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Separation Agreement</font></div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Dear Seline:</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">This letter sets forth the substance of the separation agreement (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Agreement</font>&#8221;) that Gyre Therapeutics, Inc. (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company</font>&#8221;) is offering to you to aid in your employment
        transition.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">SEPARATION DATE.&#160; </font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Your last day of
            employment with the Company and your employment termination date will be October 30, 2023 (the &#8220;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Separation Date</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8221;).&#160; Following the Separation Date you will no longer be an employee of the Company</font>, but will instead provide services to the Company as a
          non-employee consultant in accordance with the Consulting Agreement (as defined herein).&#160; The date your service with the Company as a non-employee consultant terminates in accordance with the Consulting Agreement is referred to herein as the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Last Day of Service</font>&#8221;.&#160; The period from the Separation Date through the Last Day of Service is referred to herein as the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Transition Period</font>&#8221;.&#160; During the Transition Period, you will be expected to perform the Services (as defined in the Consulting Agreement).&#160; After the Separation Date,
          you agree that you will not represent to anyone that you are still an employee, officer or director of the Company and you will not say or do anything purporting to bind the Company or any of its affiliates<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.&#160; On the Separation Date, the Company will pay you all accrued salary, and all accrued and unused vacation earned through the Separation Date, subject to standard payroll
            deductions and withholdings.&#160; You are entitled to these payments regardless of whether or not you sign this Agreement.</font></font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">SEVERANCE BENEFITS.&#160; </font>If you timely sign this Agreement and allow the releases set forth herein to become effective, then in full
          satisfaction of any obligations for the Company to provide you with severance benefits for a termination without Cause outside of a Change in Control Protection Period (as defined in your employment offer letter dated November 4, 2021, as amended
          (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Offer Letter</font>&#8221;)) as set forth in your Offer Letter, the Company will provide you with the following severance benefits<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">:</font></font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Severance Pay.&#160; </font>The Company will pay you an amount equal to the sum of (i) nine (9) months of your base salary in effect as of the
          Separation Date, plus (ii) $93,403.12, in respect of twelve (12) months of premiums related to continuation coverage under COBRA for you and your eligible dependents based on coverage levels in effect on the Separation Date, subject to standard
          payroll deductions and withholdings (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Severance Pay</font>&#8221;).&#160; The Severance Pay will be paid as follows: (i) on the one month anniversary of the
          Separation Date, one ninth (1/9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) of the Severance Pay will be paid to you in a lump sum, (ii) on the two month anniversary of the Separation Date, one ninth (1/9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) of the Severance Pay will be paid to you in a lump sum,
          and (iii) the remainder of the Severance Pay will be paid to you in a lump sum on January 15, 2024; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided, however,</font> that no payments will
          be made prior to the first regular payroll date following the Effective Date.&#160; On the first regular payroll date following the Effective Date, the Company will pay you in a lump sum the Severance Pay that you would have received on or prior to
          such date under the original schedule but for the delay while waiting for the first payroll date following the Effective Date, with the balance of the Severance Pay being paid as originally scheduled.</font></div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;"> <br>
        </font></div>
      <div style="text-indent: 72pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Accelerated Vesting.&#160; </font>You were granted options to purchase shares of the Company&#8217;s common stock (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Options</font>&#8221;) pursuant to the Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Plan</font>&#8221;).&#160;

          Under the terms of the Plan and your stock option grants, and notwithstanding your service as a non-employee service provider during the Transition Period, you hereby acknowledge and agree that vesting of your Options will cease as of the
          Separation Date and your rights to exercise any vested Options shall be as set forth in the applicable stock option grant notice, stock option agreement, and/or the Plans (collectively, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Option Documents</font>&#8221;); <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided that</font>, notwithstanding anything to the contrary herein, the
          applicable post-termination exercise period with respect to your Options shall commence as of your Last Day of Service.&#160; Per your Offer Letter, the Company will immediately accelerate as of the Separation Date any of the shares underlying the
          Options that would have vested had you remained an employee of the Company through the date that is nine (9) months following the Separation Date.&#160; Your Options shall continue to be governed by the terms of the applicable Option Documents<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.&#160; Further, you hereby acknowledge and agree that, in accordance with the terms of that certain waiver letter agreement by and between you and the Company
            dated January 17, 2023 (the &#8220;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Waiver Letter Agreement</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8221;), each Option that is outstanding and unvested as of the Separation Date (other than those Options eligible for the acceleration provided in the immediately preceding sentence) shall be cancelled effective as of
            the Separation Date.&#160; Notwithstanding anything to the contrary herein, this Section 2(c) shall not apply to any options to purchase shares of the Company&#8217;s common stock or other equity awards granted to you in respect of your service as a
            non-employee consultant during the Transition Period, including, without limitation, the options to be granted to you pursuant to the Consulting Agreement (the &#8220;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Transition Period Awards</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8221;), and such Transition Period Awards shall remain outstanding and subject to </font>the

          terms of the applicable grant notice(s), the applicable award agreement(s), and/or the applicable equity plan(s)<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.</font></font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">OTHER COMPENSATION OR BENEFITS.&#160; </font>By executing this Agreement, you acknowledge and agree that the Company&#8217;s obligations to provide
          you with any severance benefits or any other payments (including, without limitation, the severance benefits set forth in your Offer Letter) are hereby extinguished (except for the benefits described in this Agreement).&#160; You further expressly
          acknowledge and agree that the severance benefits, and other benefits provided herein are in full and complete satisfaction of the Company&#8217;s obligations, if any, to pay you severance benefits or any other payments pursuant to your Offer Letter or
          any other agreements.&#160; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">You acknowledge that, except as expressly provided in this Agreement, you will not receive any additional compensation, severance
            or benefits after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic; color: #000000;">e.g</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">., 401(k) account).</font></font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">EXPENSE REIMBURSEMENTS.&#160; </font>You agree that, within the next ten (10) days after the Separation Date, you will submit your final
          documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement.&#160; The Company will reimburse you for these expenses pursuant to its regular business
          practice.</font></div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;"> <br>
        </font></div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">POST-TERMINATION CONSULTING SERVICES</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-variant: small-caps;">.</font>&#160; You agree to perform consulting services for the Company as an independent contractor during the Transition Period pursuant to that certain Consulting Agreement entered into by and between you and the Company and attached
          as <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exhibit B</font> hereto (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Consulting Agreement</font>&#8221;,

          and the period you are providing consulting services under the Consulting Agreement, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Consulting Period</font>&#8221;).&#160; During the Consulting Period,
          you will be expected to provide the Services (as defined in the Consulting Agreement).&#160; You agree to perform the Services (as defined in the Consulting Agreement) in good faith and to the best of your ability.&#160; The consulting arrangement between
          you and the Company shall be governed by the terms and conditions of the Consulting Agreement.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">INDEPENDENT CONTRACTOR</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-variant: small-caps;">.</font>&#160;
          During the Transition Period, you acknowledge and agree that your relationship with the Company will be that of an independent contractor and not that of an employee.&#160; As a result, you acknowledge and agree that your participation in all employee
          benefits, including, but not limited to, the accrual of bonuses and vacation/PTO, if any, shall immediately cease as of the Separation Date.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">RETURN OF COMPANY PROPERTY</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">.&#160; </font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">If requested by the Company, you agree to return to the Company all Company documents (and all copies thereof) and other Company property in your possession
            or control.&#160; In addition, if you have used any personally owned computer, server, or e-mail system to receive, store, review, prepare or transmit any confidential or proprietary data, materials or information of the Company, then within sixty
            (60) business days after the Separation Date, if requested by the Company, you must provide the Company with a computer-useable copy of such information and then permanently delete and expunge such confidential or proprietary information from
            those systems without retaining any reproductions (in whole or in part), and you agree to provide the Company access to your system, as requested, to verify that the necessary copying and deletion is done.&#160; </font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Your timely compliance with the provisions of this paragraph is a condition to your receipt of the severance benefits provided hereunder.&#160; </font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Notwithstanding the foregoing, as an additional benefit to you under this Agreement, you may retain possession of your Company-issued laptop, key card and
            phone, provided that you (a) cooperate with the Company&#8217;s IT department to have all Company data removed from the devices (except any such data as may be required in connection with the non-employee services you provide during the </font>Transition<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"> Period), and (b) ensure that all Company-related documents in your possession or control are saved onto the Company&#8217;s One Drive account.</font></font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">PROPRIETARY INFORMATION OBLIGATIONS.&#160; </font>You acknowledge your continuing obligations under your Proprietary Information and Inventions
          Agreement, a copy of which is attached hereto as <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exhibit A</font>.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CONFIDENTIALITY.&#160; </font>The provisions of this Agreement will be held in strictest confidence by you and will not be publicized or
          disclosed in any manner whatsoever; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided, however, </font>that: (a) you may disclose this Agreement to your immediate family; (b) you may
          disclose this Agreement in confidence to your attorneys, accountants, auditors, tax preparers, and financial advisors; (c) you may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise required
          by law; and (d) you may make such statements and disclosures as set forth in the section of this Agreement entitled &#8220;Protected Rights.&#8221;&#160; In particular, and without limitation, you agree not to disclose the terms of this Agreement to any current
          or former Company employee or independent contractor.</font></div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;"> <br>
        </font></div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NONDISPARAGEMENT.&#160; </font>You agree not to disparage the Company or the Company&#8217;s officers, directors, employees, shareholders, parents,
          subsidiaries, affiliates, and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided

            that </font>you may respond accurately and fully to any question, inquiry or request for information when required by legal process and you may make such disclosures as set forth in the section of this Agreement entitled &#8220;Protected Rights.&#8221;&#160;
          In addition, nothing in this provision or this Agreement is intended to prohibit or restrain you in any manner from making disclosures that are protected under the whistleblower provisions of federal or state law or regulation.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO VOLUNTARY ADVERSE ACTION.&#160; </font>You agree that you will not voluntarily (except in response to legal compulsion) assist any person in
          bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO ADMISSIONS.&#160; </font>You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to
          be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">RELEASE OF CLAIMS</font>.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 68.4pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">General Release.&#160; </font>In exchange for the consideration provided to you under this Agreement to which you would not otherwise be
          entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys,
          predecessors, successors, insurers, affiliates, and assigns (collectively, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Released Parties</font>&#8221;) from any and all claims, liabilities and
          obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Released Claims</font>&#8221;).</font></div>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div style="text-indent: 68.4pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">Scope of Release.&#160; </font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">The Released
            Claims include, but are not limited to: (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment; (ii) all claims related to your compensation or benefits from the Company,
            including salary, bonuses, commissions, vacation, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company; (iii) all claims for breach of contract,
            wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all federal, state,
            and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended),</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">the federal Americans with Disabilities Act of 1990, </font>the federal Age
          Discrimination in Employment Act of 1967 (as amended) (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ADEA</font>&#8221;), <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended).&#160; You acknowledge that you have been advised, as required by California Government Code Section 12964.5(b)(4), that
            you have the right to consult an attorney regarding this Agreement and that you were given a reasonable time period of not less than five (5) business days in which to do so.</font></font></div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-indent: 68.4pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;"> <br>
        </font></div>
      <div style="text-indent: 68.4pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ADEA Waiver. </font> You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the ADEA and that the
          consideration given for this waiver is in addition to anything of value to which you are already entitled.&#160; You further acknowledge that you have been advised, as required by the ADEA, that:&#160; (i)&#160;your waiver does not apply to any rights or claims
          that may arise after the date that you sign this Agreement; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (iii) you have twenty-one (21) days to consider this
          Agreement (although you may choose voluntarily to sign it earlier); (iv) you have seven (7) days following the date you sign this Agreement to revoke your acceptance of this Agreement (by providing written notice of your revocation to the
          Company&#8217;s CEO); and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after the date that this Agreement is signed by you provided that you do not revoke it (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Effective Date&#8221;</font>).</font></div>
      <div>&#160;</div>
      <div style="text-indent: 68.4pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Section 1542 Waiver.&#160; </font>YOU UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.&#160; In giving the release
          herein, which includes claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code, which reads as follows:&#160; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#8220;A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or
            her would have materially affected his or her settlement with the debtor or released party.&#8221;&#160; </font>You hereby expressly waive and relinquish all rights and benefits under that section and any law of any other jurisdiction of similar effect
          with respect to your release of any unknown or unsuspected claims herein.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 68.4pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Excluded Claims.&#160; </font>Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Excluded Claims</font>&#8221;): (i) any rights or claims for indemnification you may have pursuant to any written indemnification agreement with the Company to which you are a
          party or under applicable law; (ii) any rights which are not waivable as a matter of law; and (iii) any claims for breach of this Agreement.&#160; You hereby represent and warrant that, other than the Excluded Claims, you are not aware of any claims
          you have or might have against any of the Released Parties that are not included in the Released Claims.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 68.4pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Protected Rights.&#160; </font>You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal
          Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or
          commission (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Government Agencies</font>&#8221;).&#160; You further understand this Agreement does not limit your ability to communicate with any Government
          Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.&#160; While this Agreement does not limit your
          right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based
          on any claims that you have released and any rights you have waived by signing this Agreement.&#160; Nothing in this Agreement prevents you from discussing or disclosing information about unlawful acts in the workplace, such as harassment or
          discrimination or any other conduct that you have reason to believe is unlawful.</font></div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;"> <br>
        </font></div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">REPRESENTATIONS.&#160; </font>You hereby represent that you have been paid all compensation owed and for all hours worked, have received all the
          leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SECTION 409A.&#160; </font>The payments and benefits under this Agreement are intended to qualify for an exemption from application of Section 409A of the
          Code or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A of the Code, and any ambiguities herein shall be interpreted accordingly.&#160; Each payment pursuant to this Agreement is
          intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).&#160; The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this letter are
          determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of such Section.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">16.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">GENERAL.&#160; </font>This Agreement, including the exhibits attached hereto, together with the Waiver Letter Agreement, constitutes the
          complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter.&#160; It is entered into without reliance on any promise or representation, written or oral, other than those expressly
          contained herein, and it supersedes any other such promises, warranties or representations.&#160; This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.&#160; This Agreement will
          bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.&#160; If any provision of this Agreement is determined to be
          invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted
          by law, consistent with the intent of the parties.&#160; This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of California as applied to contracts made and to be performed
          entirely within California.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">If this Agreement is acceptable to you, please sign below and return the original to Michelle Lee, Associate of Orrick, Herrington &amp;
        Sutcliffe LLP within twenty-one (21) days of the Separation Date.</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">I wish you good luck in your future endeavors.</div>
      <div>&#160;</div>
      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-style: italic;"> <br>
      </div>
      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-style: italic;">[Signature page follows]</div>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Sincerely,</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">GYRE THERAPEUTICS, INC.</div>
      <div>&#160;</div>
      <div>&#160;</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div>&#160;</div>
      <div style="text-align: left;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">BY:</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#160;<u>/s/ Charles Wu, Ph.D. &#160; &#160; &#160; &#160; &#160; &#160; &#160;
            &#160; &#160; &#160;&#160;</u></font> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Charles Wu, Ph.D.</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Chief Executive Officer</div>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Accepted and Agreed:</div>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div style="text-align: left;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">B</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Y</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">: <u>/s/ Seline Miller &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</u></font> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br>
          </font>Seline Miller</font></div>
      <div>&#160;</div>
      <div style="text-align: left;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Date: <u>November 1, 2023 &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</u></font> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
      </div>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">[Signature Page to Miller Separation Agreement]</div>
      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>4
<FILENAME>ny20009756x13_ex16-1.htm
<DESCRIPTION>EXHIBIT 16.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="font-weight: bold;">
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;">Exhibit 16.1<br>
    </div>
    <div style="text-align: right;"> <font style="font-weight: normal;"><br>
      </font></div>
    <div style="text-align: right;"> <font style="font-weight: normal;"><br>
      </font></div>
    <div style="text-align: left;">
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">November 2, 2023</div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">Securities and Exchange Commission</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">100 F Street, N.E.</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">Washington, DC 20549</div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">Ladies and Gentlemen:</div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">We have read Item 4.01 of Form 8-K dated October 30, 2023 of Gyre Therapeutics, Inc. (formerly known as
        Catalyst Biosciences, Inc.) and are in agreement with the statements contained therein as it regards our firm.&#160; We have no basis to agree or disagree with other statements of the registrant contained in Item 4.01.</div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">Sincerely,</div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">/s/ EisnerAmper LLP</div>
      <div style="font-weight: normal;"><br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">EisnerAmper LLP</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;"> <br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;"> <br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>gyre-20231030.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<xs:schema targetNamespace="http://ir.catalystbiosciences.com/20231030" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:gyre="http://ir.catalystbiosciences.com/20231030" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="gyre-20231030_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gyre-20231030_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>gyre-20231030_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>gyre-20231030_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="gyre-20231030.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139869395373216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 30,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GYRE THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12730 High Bluff Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">266-8674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GYRE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ny20009756x13_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gyre-20231030.xsd" xlink:type="simple"/>
    <context id="c20231030to20231030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20231030to20231030"
      id="Fact_d7ef9904c8594c1ead2b7dc5a7f681f6">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="c20231030to20231030"
      id="Fact_c9ba9617c3d64be59d69c656ec029ea6">GYRE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="c20231030to20231030"
      id="Fact_a508e00632ee49239324622d3271b368">0001124105</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20231030to20231030"
      id="Fact_625bf256eef24b09a289a1177a11d53c">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20231030to20231030"
      id="Fact_59830fad38ff4f59b595d91425a33430">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20231030to20231030"
      id="Fact_55367c8c4ef344a0a39de8bafe7c64aa">2023-10-30</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20231030to20231030"
      id="Fact_bbb7053f2737452899c5aa15f4d05ad7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20231030to20231030"
      id="Fact_f626db677e654745b1f25cbc372d7e28">000-51173</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20231030to20231030"
      id="Fact_4732621c43af477f8b8d95e8d887d283">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20231030to20231030"
      id="Fact_42d4a61ef0d0414e847dada451ee0ecc">12730 High Bluff Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20231030to20231030"
      id="Fact_b6420c2c7108463ebd3cab7583dd3bfb">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20231030to20231030"
      id="Fact_d9459c1ac595466c8575ccc8949b2627">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20231030to20231030"
      id="Fact_3809a507a8884f58814c1dd91f96414e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20231030to20231030"
      id="Fact_7846919d00c446e1913d5845494c1ff7">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20231030to20231030"
      id="Fact_e266b178ed654806ba10f1386a52d54d">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20231030to20231030"
      id="Fact_23dfd9058e894c60ad97bf32242aa3a4">266-8674</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20231030to20231030"
      id="Fact_da6b7a27461c4e46943060825e9f4ed4">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20231030to20231030"
      id="Fact_53b5741562014547a62e9d227fb969d4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20231030to20231030"
      id="Fact_833f09131d9448e1a4dcb637b4571dd4">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20231030to20231030"
      id="Fact_26ef1c56dd164887b7494a6cecb80424">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20231030to20231030"
      id="Fact_509b5ea56bd249d0be1f104fe1f41ea1">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231030to20231030"
      id="Fact_597fad79c171459b934b66c3ac950071">GYRE</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20231030to20231030"
      id="Fact_6d41e48e945b4148a2e25eb983f553da">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  R(8E<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  ,B&)7RBW&+>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R'9@!Y/ZLK'3"H45-G8SMMJ:Q8FQ-9*^_9RL31G; ^QHZ?>G
M3Z#61F6'A+LT1$SD,=]-H>NSLG'#3D11 61[PF!R71)]:1Z&% R59SI"-/;#
M'!$DY_<0D(PS9& &5G$E,MTZJVQ"0T.ZX)U=\?$S=0O,6< . _:40=0"F)XG
MQO/4M7 #S##"%/)W =U*7*I_8I<.L$MRRGY-C>-8C\V2*SL(>-L^ORSK5K[/
M9'J+Y5?VBLX1-^PZ^;5Y>-P_,2VY;"HA*B[W4BC.E13OL^L/OYMP&)P_^']L
M?!74+?RZ"_T%4$L#!!0    (  R(8E>97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MVU"Q]]:J"5#<L=^S0F:OP9;)#3_9X1N$'L;+Z?AWC*FR?7J6[<\2KC<V2Y]
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ #8AB5Y>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    "  ,B&)7RBW&+>T    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  ,B&)7F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   (  R(8E?MS#O[5@0  "(1   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  -B&)7GZ ;\+$"  #B#
M#0              @ &8#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  V(
M8E>7BKL<P    !,"   +              "  70/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    (  V(8E<<.&7J/P$  #P"   /              "  5T0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  -B&)7)!Z;HJT   #X 0  &@
M            @ ')$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  -B&)799!YDAD!  #/ P  $P              @ &N$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #X$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ny20009756x13_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gyre-20231030.xsd</File>
    <File>gyre-20231030_lab.xml</File>
    <File>gyre-20231030_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ny20009756x13_8k.htm">ny20009756x13_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ny20009756x13_8k.htm": {
   "nsprefix": "gyre",
   "nsuri": "http://ir.catalystbiosciences.com/20231030",
   "dts": {
    "schema": {
     "local": [
      "gyre-20231030.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "gyre-20231030_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gyre-20231030_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ny20009756x13_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20231030to20231030",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20009756x13_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231030to20231030",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20009756x13_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001140361-23-051195-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-051195-xbrl.zip
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MOUH?^S3OM#3['O4GJ_?=GIW_8/:9^1O2?:N5$?<XJLBN_@!02P,$%     @
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M0RE!AMQQZ\2](_YFC>/TGCDJ.$"A8AIRJ %N92-7M &>)M@TZ5RT(-YT6-#
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M"ZP)T+GK0W]^V\EZW)<EX$%?2)P=\7/#=@[WDG>]8WTI13_0Y\$>X:WN&'B
MUU?8=G0O;NV"A_:R4\?XWI D]:*_PT?C;P5L0@AE1>@*:,FV%:RA'FK!K2=J
MB.<2Q#2]N;EOW5<(>.,.6+"7<D#X =?V2X!?3)U2[ '00Z%B@G*HR5L?2D;.
M7OJ@>QK?^:!*Y]FE-F_J 9W@!A#[PLD$EE6[MSUHF>U3QE]T%=T\D!C^VQE3
MN)B,'FY G&KFBCJ#KXD\4#[/6E'6W(N_)C!N#*E>3)E$52EHA!TZ>*(>^QO*
M*F$R7=SS@2JDF,+%I/1PDV?I%3-G3]+#OL;GZ"'Y//N(R!)-IC\L?D1"=. G
MZ4V[0ZI75,925>Z>H0<=VL?RBMQ3C[^W\.YYO2 1\ BD15%,#50TX!/P<X6H
MV=I$J2EC?D50$4%YJ </2MKVBM1:7)E60"R -?JTSZS4L<(/&"LFI<0:$"HY
MN6(3,C51J6OG,HR'Y1#>!5*Q>#)[DDQ0!^1V=^I^O_4?V&9@X($8FT0YA<L2
M!Z?QLJ'K4SG@774ZUU+F(H)$J </Q%@WC-1;8/C,7E:K9W?=J7B'8VDM+MDG
M_N;?HBG,WY0[_Q]02P,$%     @ #8AB5W+P0>?F!0  #3\  !4   !G>7)E
M+3(P,C,Q,#,P7W!R92YX;6S56UMOXC@4?E]I_T.6?89PV;E0E1FQS'2$AFE1
M8;67EY5)#%B;Q,@)!?[]VL&FQ+&=,&U'IR\MY'P^_HZ_+[=#<OUQ'T?> V8I
MH<F@T6FU&QY. AJ29#5H;-,F2@-"&A\__/S3]2_-YA><8(8R''J+@_<[HRAD
M)%QA;WI_MR01]KJ]5K_5:;WIO'M_%FXVQ?"()/]=B3\+E&*/3YND5_N4#!KK
M+-M<^?YNMVOM>BW*5GZWW>[X?WV;S((UCE&3)&F&D@ W/(Z_2O.-$QJ@+.=\
M-GR_8)%*T/-/<UD1XEM3P9IB4[/3;?8ZK7T:-B1%$:XQB8+O2WA94Z??[_MY
M] 3EB8@C]:ELOGJ>=UP_1B-\CY>>^/_'_=@ZNN\+A)_@;((6..)3YL.SPP8/
M&BF)-Q%6V]8,+\UY(L9.:<3J],7J=-Z*U?GU,;/_%'HK8:8YS5#T/#SS?&6N
MI6F>3OKVN9;61?GV.5>9[^3X!ZSRV31/)SW%C-#P<Q*^/'%]JN<B/\L0^P%6
M*4_V] )>GO4%5 EK\4,^B@YIMB"4GY;X>0JGK8#&QXD^T6 ;XR0;)ES$C&2'
M<;*D+,[/$M4UK Y,G &ZO4Z[U\X9NO.=,]XPG')@'IGP#87)\#[#28A#-9W@
M^CPUY0P4AX@&A6DC<7ZDK"Q4RJ?-54IQT%K1!S_$Q!>%BP_Y"N35\R__CBB_
M,!@NTHRA(%.9(J'8H&&,<8:B."WFOSA1M4QSGE'C:0I)FL50D>6YI$-69(Q8
MH#+QCP4]RR=QB? WB/%\S6!-HI,5EHS&MI6D3NKG]*Z\0@8OHUYQ)&4A9H-&
M6US;\8%+S)C<\1R\<]+1^=[YD@(..=M0,+Z)T$I3T!B3ZZ#%X&GH(E\AHC94
MJM@!K**RW>E,^HD?XBW[HQ&C[9@:!IZZ=8JIN:MJ*:3:W5>@]@U) Q3]C1&[
MX5M2B]X6E*9X"057<W=!-54O)9&Z]UZ-[D??5BMOP!FU+^"@JV\OZB+]"VFD
M WX#[(#CI>@-B?#M-EY@I@EO"\NE*8?AR5Q10H6ZY=%2U#?@1;W'*R(*2;);
M%.OG;A>D(*X.@2JPLY1:(NL9I-!OP0L]XJ4Q%(WYK>G^*SX8E;9@"E*7,%"U
M=A=32^Q2"JGV._!JCY. L@UE>7TS7B8>T2TOYC"BH7DOKS6BX(2*$5!]<4FA
MM5Q2D5!ZYCUXS\S1?ASR:LF2'']J<9SL*[ %GUBQ4!U2K[A:WK"FDJ[H@W?%
M, QYH:G\-R$)[A@=X< 5W&#$075"=5&U7&!,H_H[D-MT-OK=FA;HUK1 ]S59
M0"_J.RW0?;0 Y!Z?C7ZOI@5Z-2W0>TT6T(OZ3@OT'BT N?%7H#_B'^_8G.X2
MEP'**)/\YRC@XEL+ND3Z\R1*>,B=OP+Y_,KVCDT9?2#'9W.LZEN@)@N4H,!]
MX"[M$C.4,BE'P.\$*CL?;W.<QX$BQ'@04!#@RIM+N6CW5QF4TO#;@Y+YE*89
MBOXA&VO[P 4TJ:X!@6OO*NL2!VAYE \@=P_%.6O(,#(H;PJI)T(*(7CJ.JA7
MZ%D<J12$W!$43\Y&TS5-S+_>V,)R.<IA>&I6E%"A:'FT4A5RSVZ&@RWC7NQT
M%W-1IJ:J+2R7I!R&IVI%"16JED<K52'WW.8,B2?Q9X=X02--4F-,+H86@R>F
MBWR%DMI0]:0,Y+[9+2V0-CSDYD#(53$BX E;74B%O,8$2F3(G3%UA/F\#]8H
M66'##^@NB'8D+D+@Z5RCE)I'Y&(&I33\!MCG&+,5]^D71G?9>D3C#4K,-[].
M9.%NR(*$)W_]PFK=#UD2*3- ;HK]R3V<X81SCK>)_%5/?Q3.B9'K9,' D[Y.
M,16B6U(HN2%WO&8T(@')N%>_H0PS@O3+,CM '>$- '@J5Y91=70WC%?Z0NYS
M31D6MA3OX>1O4(AW=]C=<EFZ3ZX&RH5R >'I7KNL"OU=>90/(/>Y-/[C--UB
M5ML-5KC9$P8X>&=4E7B9/PS9E$N>VDN[]DM+..$;Q"OIQXCX(U[A_O _4$L#
M!!0    (  V(8E<5XI0R_!X  ''    4    ;GDR,# P.3<U-G@Q,U\X:RYH
M=&WM7>M3XSJ6_[Y5^S]HF=H9J$F"GTE,TU310/=E;S?- +?F[GS9DBTY\;1C
MY\H.D/GK]QQ)?B4.!)I'NH>N6Y<DEJVCHZ/?>4K>'^>3F-Q.XB3;N_5%'+W?
M&N?Y=&]W]^;FIH>_]%(QVK4,P]Z-DBRG2<"W=/LX2K[=T1PO^S0KF]\NM;^Q
M96O3\[Q=>;5LFD5M#>&QYN[O7SY?!F,^H=U%>K![5MU8IZ:_JRX63:,L=2QS
M<-=@58OBADSD9>.09KYL"#]"8\LNGWJ[ZH$F<@]&R'__</&Y:IZWMZ^:[N:"
M)EF8B@G-HS3!WHRN875-J_:0;L:#QH/@>V^47M_Y'-/M&L.N;1;/F67=$:73
MY4'J"XV!,K[ YJ)'N-!H&*2S)!?S]L;Z8O.&F1 \"5;=H:\VB<E%-Y]/>=;.
M3+B\BY?Q'JMKV/4QYV*E!'B[<+5HF- HR-I)DI<:]&11T-X4+C0;YE.QHB5<
M:33EM\&XO2E>:7*0ARN8Q\-&P]%<\+)E)'H!S6D\SW(_2K,@ C;SK!>D$WF/
M:=B&OF_U"D8HV3KXS_\@9'_,*9.?X',>Y3$_V-]5?_6/_]7MDL]1P).,,Y*G
M>^2#2"D3$1MQ\C%*8%E'-":7:3Q#><W47?+?<1K,)CS)22 XS>'N618EH_K]
MYQ=?PRCFQ+)[7L_LN>9@6+O_*)W.130:YP2H=DF7X/CJMW>[!9$3GE."H^WR
M/V;1]?NMHS3)H>ON%<C3%@G4M_=;.;_-=^7HR2[<N[^KAP\?_93-29;/8V!U
M".V[(9U$\7R/_.4JFO",G/$;<I%.:/*7#I&_=$C&112^([)U%OV+[Q'3F.;O
M"/;2I7$T2O9(S$/X)4CC5.R1/QGRWSOBT^#;2,"J8MWB4BC_O<-IV6?1-8G8
M^ZWCR_./$:+"+Q%C/-DJZ&-1-HTIT):D"8=;]J/;/1P)%^JC;"T_0H,SF 01
M!22A$[R51WN',"L,9^9C3$=;LJ>/-,C_CPUXZ'F&$PQ=SPE,>*#E#UC@TD'8
M'YIA7S/R-K] R0T*<<O32O 4<+W? K#;"Z-;SH"-,6B6 _EG?[=!TFH*3Q*0
MP?D%'T49XF%^!E=JA :>3[V^.0ALUG=\[GJL[P5]M\\#P_(X78/0@T__>W%"
MKGXYN3@\/_GMZO3HLD-.SXYZ#Z3P")@H:'R:,'[[*Y_72*2N,>2@SFR+<\>S
M;,^VG+YE,=L:F+[='ZY!(DB*:5J.:;AK4W7) 7B!KA/ &IJ,^ +?^I;KAQ;P
MB8>6XQL>M88>-<W! /['7#M8@ZBSP\OCP[\M$;3;%#O!0RXD,!WLH[FPETE#
M !Y+I/FP-Q;8 P);MWAV[S9C6_HRJH'W6UDTF<8@._N[S6>H[NI]R*]9.A/R
MFS2/]O10Y.A;AZ+;<3F3Q;>(X?<PXH+(_GBKOCXZ_;4Y/XLW'Q0_-9\^!6ZE
MK/@&1I'(CP$:#Y"HKFET;:.XK[I6DLE6-"VN%-^+3G8;?"B85G)IMP8:NX X
M$@8!2]5'":MC42".GPIHJ &'J&]=/\WS= *H-[TE61I'C/@Q %MY/4^G>\19
MO#CFB.D2*V\K9-3P=P<R-F 5]%'.Q3LRH6(4)5U$V3U"9WE:_B14+_(WA?9R
M2#@ZLN^+ZI?:V!NC7_BBOA;\6()X$*?:0Y<?W/)]Q>.*H3U>"0U1"<D?;C2O
M_31F0.)O9Z=7)\?D\NKPZN1R/YO2I*'QEFY?M_>VP>/3#RY/CGZ[.+TZ/;DD
MAV?'Y.3WHU\.SSZ=D*.O7[Z<7EZ>?CU[.:Y8J[CR]\/+7T[//EU]/>N0X]Y1
M#^P,U_$V@##2Y&H;16N(YS/*4\U8JX-%N<)Q@=]$+!_O 4__>RTSJ+C4-H(F
M"#UDZ4M6_?E/9M]X]_'KQ1>R4H$6-JNR&TO%Z7I#VP@ILX=AZ(2NY[N>RSS3
ML5QJVPX:/O<JSF'WUV6MJ6;P]9 "1:\^C1L\B6M(_P9!\,HU#7AX<7)V12Y.
MSK]>7*W$8.OI,/A\)K(9V-#@O!&P#]%+(Z9-4D%,=YOMD#0D^9@3;3I&T$=A
M/9+#(,?+IF<[+RV3:K&^=*]H1^&(!9^F(B?;Q7=.P9+B64[X-3JTZC)G.WMD
M>087)OQ>J#F7YMJ),N+JF./:_4$P#!P>VHY##6I[C ]]&O)!T'<H?: WQN#I
MW0G<,482NHS.NW,85A?<RH.O09[Z8/':1D<ZV<M )27I9Y>!E7JN,<D8Q.M&
MMUWE[NRMYY >? )7AUR-N:!3/LNC "@X38)>P=E[%?US\GG[Y!8&(453"7_A
M=A.:D6S* W1I&(D2$N49 6P V1<[ZU*I(B#/) LY]6,.C(ACX&,0):/W6ZB,
MX?N4,E9\?YJPCE:"IH%:4+LXH/%B.LV@3?%IC?!/7>/632CI?N6B8585+?9S
M5@Q#TV%;/<,$2JZY 'FB<=&E\LH6K+-UQ&A1>S^#]KLGG (K(A4 K3+T?9D#
M8AVIR/-1RNK0Z/O^P'#MT!K8 \>UAIX7N)2:;N@PPZ5L\#!HQ 6-_G;.IR*]
M1IH0$X]Y3&^H6(Y9+6C9YI)M_I:S->?2VMQY7%QZCQRA_1Q#%"-_&U06_K=S
M[SC5,)]06C]&,8=KH#AKHAGVK3[S^X,![[L."*=OAI8;^($]L-B 6VO&_;JN
M:0Z6U?";Z&V,Z+TB2E[1VU,=: PD4BX)H3.PK;YE!HY-0V<P"(?^D'DN'[+A
M<,"LH;V&$+I]#,P:AFL\H11*!;>[H.&>1NOEZ?35)Q,L*:FTT+=*P:<2Y)_@
M4F4LDD[7L_IZ%<NE/0E67%37I3O/ !*;P?'G0XC-&-_V43J91%GVP@*$NHTH
M7'F3G1]6=DXO+LG)9!JG<RY>4GJ:ZHF<I;WUA*A%/Q2?,$HJG;U&=N;-WWPY
M?]/Q'N%OMLG(QAM8AXP)GF7ZS^<HX6;=N+*80_LF#PUF.*;#A\Z 448=U^3<
MX,$Z2703'%>#_ (TD0_Q+ S)L8BNU_0TVTVM!S#V=9VF9=Y:=<>^[UA&8 4#
MTQ@Z?9O[S ZH/W"'-F.V'_IK\/9R%H$%9JUKMWXW.U]?3H_@XU=QE=XD]5H>
MSW&]P*2!Z[E.OQ\,W8$;!,'0<SP??(,U0B0'EZ OCB,^2A<YV5EF%EF=4FO0
M*NWCK^)<I->1+ @M";:'AD==8T"'PZ$3NL.AZ00F8YX9>GU<9FL0?'2X*L-V
M_XR_><P-J-_<(7['0CE/LYS&_XBF"^'$ 6"-9WK,, +'Z7/3,VWF#AW7P2JX
M,%QGK7B6:6^8I[Q*7V^(;:KG!!,.4P%8$$UI3/@M#V8YZ$+X&<Q'GKTY'_?,
M\<:.;QO6&<&%]H*F_X^:>%2]5N6N?_[3T#('[S(P[6,^':<))XGTQ3L8UHEG
MZ&@0*CB%66.\+0G]:-^N%5ZW5^(KVAZ'0,@"HG*KW_?-P9"SONL,C;Y/32,T
M[6&?NA9S';8&HO:7+;B=U4;&YQ06P#ER:BD8:MDL9)[A#CD8/T'?H,P;^*%M
M68Y%J4V=-6B!T72'_8'S@+SXJZ9TVRM/]*X!\J':-E DH1]&W LH]%4>TL81
M6G,W7GV&GQ(&ED((I3?0(6AG2\'7./F<W6K#ZE7J3[8_I@(6NBZ,$#)G#%^I
MLEP BT.B"J5 +:,W0V*:%<5!:Y='?#^QQJOHK/MZ7:S-JRO[EC)#JUX,_MJE
MA2]4V?*8B7N:/H_&//@FR_[H="I2,, Q;>6GM\3G<7J#DHT74?[)L/LK":,8
M38XH _LCYPF36\% Z">S.*<)3V=9/"<9S:,LG,L[]0VI#U2K(+ N,ZP5%\&T
MXFI*YOI:)2%A&@,5^ "LR(@P^9&1[94X8SS2RI&/VB,1Z,4H *YDG#> [1-/
MN "OY#0!BF>J<O*P9_44DW;V?GXY66EO_5U$.0@")J=FB8[S9_7P$^W[ VH-
MG+X9.!S<:\<V^L;0<KD7.IRM870M5>CX:1K[% 0C!SE%=MQ:?1,9TK3)B"8-
M.JC31J:U,MB+6<R)8[F5Q"E97*B#Q?+7;7- CCY>$,LV>G#'BU6];>"<7Z:P
M3( SR>@+H 5 1ERO5K5]=^"8;M\R3,=U!K1O<8]9UB#TO;[WK!->T04 KPA;
MGFW3H5W3:IOP1K5S.=V.T5.W_#O/^+G@N,+159";(A#YQ=<P;/A70]L.#<^T
M3>8YSI";U&&!W[<'ON,.3/:L,P_T=8,:@7>L^6KFM3BPKK7M[ZPG!ZKMFR24
MC#[-LAD7[?)@]7EH!FZ?,;/O#(<#?^!X#NT'//"'AF-MJ#S8O.ML!^O)@VZ[
M,?*PQB:PIR&AIAN5'<<%6(+3M@TF<G%IFP\8N&PKO676JQ(29W6Z97&OK>X9
M_26UK19&,XYRWD6N<?1];@1]3/SWB<3S"6WT)5Y?X;D4:CM.,"8!>-O90F2@
M,> '9 DVMI*^;>D_<I"V\3U2]OI,N!)4QKTOYQ,_C;>?)37TD\WX'4/\$6;\
M3&](DLN=%^H8M L@7C!^0JBYMZ"MTG8O5N?<IA->.[-WGX.H3Q\Q+5]"==T]
M-#S?Y=3M^\QR/&;XW Q-PPGACV-R:JY3W0&V',S]99X&WUYF9\1FYL^?6R5L
MQOA6"IE6 TH+-+;H#T+*!EY@#DS']7S/=OQ^/[!IX+F&,5A'PO!,H%?;<[,9
M;/]Y2Z*U6-VWD_?>(Y(.KL"C.:,9HW^0(SK%X#'Y0L4WGK?NY7V0Q#Q)$<33
MN'JG"4.WF1-_3@*9+9C ($'S<KFQ92&4'V4$V H^-^971F0DTIM\C-[W%,/[
M-".,AU&B]A"KX*OAMAP\4)TW8)-M%,7!.QEW+1I'<O?Q%'<?5QQ*A7;A+;]K
MK7F:0?ET=.>K^VK/7SLI_AK!GG_.LCP*Y]_?[<F*&;NGGJZX[9.\ZTC=5#]G
MC(%2=X;<<US?,9TAM;CE<M\;VJ'KVNR!1Q<\) 3TXAQ\C2C=:7C':L,2H=:E
M&RTEX,:P,'G, SR;,4EE_&:6<=D*:-9I/CR.-)(Q'76N&,Z,["N>8^<W$72-
M(I/  %)1+4O!KR,\,C(LSXBD@3Q'%._"XV 9%2Q3"3ZV*HID;],RBE1?Q[W5
M)4^/L?[__"=OX#CO'EAF\&0RU#B?J!;+*XX'6O,8MJ63UNK'L"V=T?9*Q[ ]
ML$!AT3.[Z_8@YE1(!W=<=J_&+F5"_U(>6B=YKZ)([[<^7)Q_/*<C_D%P^@T+
MVAJG(M4ZF4*CKH^MNC3,<2YH?$/GV8I'K3PC2\^-MIC4'"S3KR;5J!W!I&*6
MCZR:6+?8X56*25I+FDZ37*1L%N2IF).S-&\M 7LM[7F(\ 4PI\H?BD.!.ABA
M6#Q1AVPCA&%=IV6\.XI3>1(N'O@C?S+?[73(BA-BR+8J.X(>OB7I38+6U.I2
MOAVR/064%HBBC9**>I^=DA#]'$T$X#@C4JHEX+;>@E06-*,6SV:3B3S<%^^H
M<8,F"4A@ !=\//87*[U!:?B@#"2RM["C?&I=$^1CFH-\B9R"Y?BA>-)1[4F'
M(\%5LJ?^S+N;5DQGDG:*9>@5KXYYP+&(E%A].7N68@S8N!.E%.%98/('8V)Y
M>GJQP>%L!))53GFK!?G(LM G$MGV)9;S"7%ZADF.I'[-I)&^7(M\A Y=*)7^
MH=+D</5'&238$0HDCJ,,MU.#.0)F!9[;.\4I!>FYJ!):YS,_!JOWL+)7/D9B
MLGDCW3HXKZWUA?5Z$F4)%X<3L-K(Y\_GZ/'(E5'[O5QQ\/QKM0SP.5&-*XTT
MG^1*S8H+@2O(Q@)&>N1KLDQ)6UD7-I(V)"]JP^I0),6-SEB42V,3&^-1940M
MOG)UVF9M=6*C;.9G_(\9THUE:B*::)L5QP4*<30&RQ*\NTD=F3LJFBRQ#(>*
MJSLN2M**T69U$CMEAT656POYATDR R&[4 ?)P1BQEJYBA6E@5=VZ@UMZ^M]F
M\@PNH%-UD!4]X(/_5C[X#]4LTP]7F*6?# /_GUG"*PV%';6Q1V9PY63(HPCR
MG/,&U"Y<*X4*N%(H"TFSGX+!C[^R2'!4Z!E\DHN1LXHQ=;$%>6P\X4&"N8'(
M!/YV<_')48EJ!I?FN:$FE7_74+YHT$L-5GE9\B K5'*94FMR7NN2EMTI:O#!
MA'F1#F$U*^BNHP:6T1QV#2+%23J-$KEX!<XC&+\1%D=#A_I"!QXAR U,$78]
M1V&,U4%R\/,D9>HS8@ZXG8G6\3GXKVKE9T$Z!1B#MK6)U3O%8F0ROPU 6LNA
ME>#26I;YVA._'>V0U9/?.O?/-[^=8CZ1_T#SE IX9C7;^'T$9NA8=J;P&LPP
M+8=7&A:E-*K5UD+;F%YSXG.>H%$(#Y13#<9B^32I)W2XZ2:*8TE3E,RX-+3(
M*,66\!L(1M)3NIL<2L@(9@@9:*6@0T"L0O^UT:'@"W!BDA60?I0F,C:-Y2;G
M\A!Y)$ZFE?3N*B"A)OHT S[P/(^5E1ERFL] IJ76Z!3Q"SFF3A%CJ2U5.949
M/GP,E@AB<4BC&$F6E=?77.M"I"FKU4G?1:4_7PG4!4=AQ<1@>F.XYX]9)%2]
M]H1^XVH\4SI7TZ195]"V6(A]%Q49K!!YQD>2@QZ"V< %J39TRF,BY1M@<A)'
M0  LZ'FA: 6-,E@]J*S1@L3Y8NG,SPGUTUDN[Z4^*-9\CM2M(15?: +N=F'7
M2X9/8YI(.Q;4!&H=-4P +?!5I$($@03'/4L)XUD@(K\N3\5SKQHEZ6U"SE(9
M-RNE1J(C8H9F+LKY1+[!1/!L%H/PB'0B&0XCA17$R[!S#0![&N$W$\8 QY8
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M;).JI^=(ZDR$].ABC&(V+;,I^+?:#1N "^0] I5.0NN# *2$]\01,FE+I(B
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MVD6@(5K'AFG/2\<KF1."A*@+ZE=R3S DTOM &!V=A]/,+]IF?C6LIHL7@8]
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MI/G\Z%MR![<X= ST8PT(^E;C:#I?,F\2VG0]672!3*J+/#3TP;L>."GB7FF
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M"JJE$TU2A/L?.!6R),0MG1'TRZ?)=.?8SI/,MWWS$Y: Q]95;/D2<-$_Z??
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MO3G<VFFWI=K:V=G:V=_O!+M;PV#;74)O,8O,6US\!L-3I$;R>J5KYPL^9X$
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M5^'=8&3?(]D;(/!1NT*7L+J(##RP[DXDZ/[++/]B#:\++44_!@849P 'V)3
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M:58!H.I_*IE8GZ*HILCFJWI-I!CK77V])J;PH EI02+R(1:EL')'PF>QA?S
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M^+L<JFMVCC>N0W!OWL1].J&1QYF5 9[7[6('3:\J^-=C>H4-?>1AM-/S(8C
M<2.(G"-T6\^F:Y'&Z4-^W,5H;.:^RODE_!U[5[MX<) B7]O#:/W9?GK[;)C%
M<_HP*:<)?/C_4$L#!!0    (  V(8E<[.=K& @,  '4/   8    ;GDR,# P
M.3<U-G@Q,U]E>#$V+3$N:'1M[5=M3]LP$/X^:?_A5J0!4I.FY64T+4A;*0BM
M @1(^^PDE\0CL2O;H<U^_2XO;<,&"$UB5!M6I)[<Y^Z>.Y_M\S V:7+T_AW
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M92TR,#(S,3 S,%]L86(N>&UL4$L! A0#%     @ #8AB5W+P0>?F!0  #3\
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M,# P.3<U-G@Q,U]E>#$P+3(N:'1M4$L! A0#%     @ #8AB5SLYVL8" P
M=0\  !@              ( !/WX  &YY,C P,#DW-39X,3-?97@Q-BTQ+FAT
7;5!+!08     !P ' -D!  !W@0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
